Catalog No.
MVV10201
Species reactivity
African swine fever virus (ASFV)
Host species
Mouse
Isotype
IgG2a
Clonality
Monoclonal
Immunogen
Recombinant ASFV F317L protein.
Target
F317L, F317L
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
QPB67569.1
Applications
ELISA, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
1A012
African Swine Fever Virus F317L Protein Inhibits NF-κB Activation To Evade Host Immune Response and Promote Viral Replication. PMID: 34668754
Efficacy of Dasatinib in a CML Patient in Blast Crisis with F317L Mutation: A Case Report and Literature Review. PMID: 26673003
F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib. PMID: 21489624
Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia. PMID: 24385789
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. PMID: 18818391
[Chronic myeloid leukemia harboring T315I and F317L mutations successfully treated with interferon-α and ponatinib]. PMID: 30726822
Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: is that true for all the patients? PMID: 21605905
Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib. PMID: 21962337
Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation. PMID: 19545285
Treatment of chronic myelogenous leukemia. PMID: 26796903
Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation. PMID: 19811824
Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia. PMID: 17114651
A 2,6,9-hetero-trisubstituted purine inhibitor exhibits potent biological effects against multiple myeloma cells. PMID: 23810672
A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis. PMID: 21264552
P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia. PMID: 18828913
Cumulative mechanism of several major imatinib-resistant mutations in Abl kinase. PMID: 32719139
Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment. PMID: 12783380
Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines. PMID: 18191450
ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan. PMID: 23009571
In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. PMID: 17982022
[Dasatinib treatment based on BCR- ABL mutation detection in imatinib- resistant patients with chronic myeloid leukemia]. PMID: 26876246
The landscape of BCR-ABL mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors. PMID: 32011024
Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML. PMID: 20607847
Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. PMID: 21509757
[Clinical Analysis for 42 Imatinib-resistant Patients with Chronic Myelogenous Leukemia]. PMID: 28446278
Genetic Characterization and Variation of African Swine Fever Virus China/GD/2019 Strain in Domestic Pigs. PMID: 35056045
Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. PMID: 20310049
Human immunodeficiency virus type 1 evasion of a neutralizing anti-V3 antibody involves acquisition of a potential glycosylation site in V2. PMID: 20032207
Dasatinib in chronic myeloid leukemia: a review. PMID: 19536317
Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE study. PMID: 24236021
Differences in Variants in the Structural Domain of BCR-ABL1 Kinase between Chinese Han and Minority Patients with Chronic Myeloid Leukemia by Sanger Sequencing and Next-Generation Sequencing. PMID: 36167055
Successful treatment of Philadelphia chromosome-positive mixed phenotype acute leukemia by appropriate alternation of second-generation tyrosine kinase inhibitors according to BCR-ABL1 mutation status. PMID: 24532437
Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients. PMID: 20673586
A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl. PMID: 20604564
[Variables associated with BCR-ABL kinase domain mutation in TKI-resistant patients with chronic myeloid leukemia]. PMID: 32654459
Emerging BCR/ABL1 Mutations Under Treatment with Tyrosine Kinase Inhibitors in Paediatric Acute Lymphoblastic Leukaemia. PMID: 25895602
Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance. PMID: 26999421
Co-existence of isodicentric Ph chromosomes and the three-way Ph chromosome variant t(3;9;22)(p21;q34;q11) in a rare case of chronic myeloid leukemia. PMID: 29541231
[Allo-geneic hematopoietic stem cell transplantation in treatment with T315I mutation of chronic myelogenous leukemia]. PMID: 25573310
[Correlation between point mutation in ABL kinase and clinical outcome of chronic myeloid leukemia patients]. PMID: 25152116
Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile. PMID: 22210874
Quantitative monitoring of BCR/ABL1 mutants for surveillance of subclone-evolution, -expansion, and -depletion in chronic myeloid leukaemia. PMID: 21955823
Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML). PMID: 33581133
[Clinical significance of CRKL protein phosphorylation level in the treatment of chronic myeloid leukemia with imatinib]. PMID: 21429397
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? PMID: 19880502
Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis. PMID: 21193419
Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors--a single center experience. PMID: 26247667
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. PMID: 11964322
Use of direct sequencing for detection of mutations in the BCR-ABL kinase domain in Slovak patients with chronic myeloid leukemia. PMID: 21895409
New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. PMID: 19557636
[Detection of ABL kinase domain point mutations in chronic myeloid leukemia patients receiving imatinib treatment]. PMID: 18504184
For research use only. Not for human or drug use.
